Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

2.

Borrelia-primed and -infected mice deficient of interleukin-17 develop arthritis after neutralization of gamma-interferon.

Kuo J, Warner TF, Schell RF.

Pathog Dis. 2017 Mar 1;75(2). doi: 10.1093/femspd/ftx014.

PMID:
28175297
3.

Clinical laboratory assessments for Mycoplasma genitalium in a high-prevalence sexually-transmitted infection community reveal epidemiologic dichotomies with Trichomonas vaginalis.

Munson E, Munson KL, Schell RF.

Expert Rev Anti Infect Ther. 2017 Feb;15(2):133-145. doi: 10.1080/14787210.2017.1265887. Epub 2016 Dec 10. Review.

PMID:
27894204
4.

CD4+ cell-derived interleukin-17 in a model of dysregulated, Borrelia-induced arthritis.

Hansen ES, Johnson ME, Schell RF, Nardelli DT.

Pathog Dis. 2016 Oct;74(7). pii: ftw084. doi: 10.1093/femspd/ftw084. Epub 2016 Aug 21.

PMID:
27549424
5.

Arthritis is developed in Borrelia-primed and -infected mice deficient of interleukin-17.

Kuo J, Warner TF, Munson EL, Nardelli DT, Schell RF.

Pathog Dis. 2016 Oct;74(7). pii: ftw077. doi: 10.1093/femspd/ftw077. Epub 2016 Aug 4.

PMID:
27493062
6.

Clinical Laboratory Assessment of Mycoplasma genitalium Transcription-Mediated Amplification Using Primary Female Urogenital Specimens.

Munson E, Bykowski H, Munson KL, Napierala M, Reiss PJ, Schell RF, Hryciuk JE.

J Clin Microbiol. 2016 Feb;54(2):432-8. doi: 10.1128/JCM.02463-15. Epub 2015 Dec 9.

7.

Detection of Mycoplasma genitalium from male primary urine specimens: an epidemiologic dichotomy with Trichomonas vaginalis.

Napierala M, Munson E, Wenten D, Phipps P, Gremminger R, Schuknecht MK, Munson KL, Boyd V, Hamer D, Schell RF, Hryciuk JE.

Diagn Microbiol Infect Dis. 2015 Jul;82(3):194-8. doi: 10.1016/j.diagmicrobio.2015.03.016. Epub 2015 Mar 25.

PMID:
25934156
8.

Interleukin-10 (IL-10) inhibits Borrelia burgdorferi-induced IL-17 production and attenuates IL-17-mediated Lyme arthritis.

Hansen ES, Medić V, Kuo J, Warner TF, Schell RF, Nardelli DT.

Infect Immun. 2013 Dec;81(12):4421-30. doi: 10.1128/IAI.01129-13. Epub 2013 Sep 16.

9.

Insights into trichomoniasis as a result of highly sensitive molecular diagnostics screening in a high-prevalence sexually transmitted infection community.

Munson E, Napierala M, Schell RF.

Expert Rev Anti Infect Ther. 2013 Aug;11(8):845-63. doi: 10.1586/14787210.2013.814429. Epub 2013 Aug 14. Review.

PMID:
23944153
10.

Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents.

Schell RF, Sidone BJ, Caron WP, Walsh MD, White TF, Zamboni BA, Ramanathan RK, Zamboni WC.

Nanomedicine. 2014 Jan;10(1):109-17. doi: 10.1016/j.nano.2013.07.005. Epub 2013 Jul 24.

11.

Retrospective assessment of transcription-mediated amplification-based screening for Trichomonas vaginalis in male sexually transmitted infection clinic patients.

Munson E, Wenten D, Phipps P, Gremminger R, Schuknecht MK, Napierala M, Hamer D, Olson R, Schell RF, Hryciuk JE.

J Clin Microbiol. 2013 Jun;51(6):1855-60. doi: 10.1128/JCM.00455-13. Epub 2013 Apr 3.

12.

Assessment of screening practices in a subacute clinical setting following introduction of Trichomonas vaginalis nucleic acid amplification testing.

Munson E, Miller C, Napierala M, Kramme T, Olson R, Munson KL, Olson S, Hryciuk JE, Schell RF.

WMJ. 2012 Oct;111(5):233-6.

13.

Screening of male patients for Trichomonas vaginalis with transcription-mediated amplification in a community with a high prevalence of sexually transmitted infection.

Munson KL, Napierala M, Munson E, Schell RF, Kramme T, Miller C, Hryciuk JE.

J Clin Microbiol. 2013 Jan;51(1):101-4. doi: 10.1128/JCM.02526-12. Epub 2012 Oct 24.

14.

Hamster and murine models of severe destructive Lyme arthritis.

Munson E, Nardelli DT, Du Chateau BK, Callister SM, Schell RF.

Clin Dev Immunol. 2012;2012:504215. doi: 10.1155/2012/504215. Epub 2012 Feb 22. Review.

15.

Interleukin-35 enhances Lyme arthritis in Borrelia-vaccinated and -infected mice.

Kuo J, Nardelli DT, Warner TF, Callister SM, Schell RF.

Clin Vaccine Immunol. 2011 Jul;18(7):1125-32. doi: 10.1128/CVI.00052-11. Epub 2011 May 25.

16.

Identification of Escherichia coli O157:H7 surrogate organisms to evaluate beef carcass intervention treatment efficacy.

Ingham SC, Algino RJ, Ingham BH, Schell RF.

J Food Prot. 2010 Oct;73(10):1864-74.

PMID:
21067675
17.

Trichomonas vaginalis transcription-mediated amplification-based analyte-specific reagent and alternative target testing of primary clinical vaginal saline suspensions.

Munson E, Napierala M, Basile J, Miller C, Burtch J, Hryciuk JE, Schell RF.

Diagn Microbiol Infect Dis. 2010 Sep;68(1):66-72. doi: 10.1016/j.diagmicrobio.2010.05.002.

PMID:
20727473
18.

Significant differences between the Borrelia-infection and Borrelia-vaccination and -infection models of Lyme arthritis in C3H/HeN mice.

Nardelli DT, Luedtke JO, Munson EL, Warner TF, Callister SM, Schell RF.

FEMS Immunol Med Microbiol. 2010 Oct;60(1):78-89. doi: 10.1111/j.1574-695X.2010.00721.x.

19.

One-year duration of immunity induced by vaccination with a canine Lyme disease bacterin.

LaFleur RL, Callister SM, Dant JC, Jobe DA, Lovrich SD, Warner TF, Wasmoen TL, Schell RF.

Clin Vaccine Immunol. 2010 May;17(5):870-4. doi: 10.1128/CVI.00524-09. Epub 2010 Mar 17.

20.

Cost-effective modification of a commercial PCR assay for detection of methicillin-resistant or -susceptible Staphylococcus aureus in positive blood cultures.

Munson E, Kramme T, Culver A, Hryciuk JE, Schell RF.

J Clin Microbiol. 2010 Apr;48(4):1408-12. doi: 10.1128/JCM.02463-09. Epub 2010 Feb 10.

21.

Efficacy of bilateral bronchoalveolar lavage for diagnosis of ventilator-associated pneumonia.

Zaccard CR, Schell RF, Spiegel CA.

J Clin Microbiol. 2009 Sep;47(9):2918-24. doi: 10.1128/JCM.00747-09. Epub 2009 Jul 15.

22.

Human Lyme disease vaccines: past and future concerns.

Nardelli DT, Munson EL, Callister SM, Schell RF.

Future Microbiol. 2009 May;4(4):457-69. doi: 10.2217/fmb.09.17. Review.

PMID:
19416014
23.

Cost-effective frozen master mix modification of a commercial methicillin-resistant Staphylococcus aureus PCR assay.

Munson E, Block T, Voegeli JT, Hryciuk JE, Schell RF.

J Clin Microbiol. 2009 Jun;47(6):1888-91. doi: 10.1128/JCM.00506-09. Epub 2009 Apr 22.

24.

Expanded role for interleukin-17 in lyme arthritis: Comment on the article by Codolo et al.

Nardelli DT, Schell RF.

Arthritis Rheum. 2009 Apr;60(4):1202. doi: 10.1002/art.24415. No abstract available.

25.

Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease.

LaFleur RL, Dant JC, Wasmoen TL, Callister SM, Jobe DA, Lovrich SD, Warner TF, Abdelmagid O, Schell RF.

Clin Vaccine Immunol. 2009 Feb;16(2):253-9. doi: 10.1128/CVI.00373-08. Epub 2008 Dec 3.

26.

Mycobacterium tuberculosis susceptibility testing by flow cytometry.

Schell RF, Nardelli DT, DeCoster DJ, Kirk SM, Callister SM.

Curr Protoc Cytom. 2004 Feb;Chapter 11:Unit 11.7. doi: 10.1002/0471142956.cy1107s27.

PMID:
18770792
27.

Detection of borreliacidal antibodies by flow cytometry.

Callister SM, Jobe DA, Schell RF.

Curr Protoc Cytom. 2004 Nov;Chapter 11:Unit 11.5. doi: 10.1002/0471142956.cy1105s26.

PMID:
18770791
28.

Impact of Trichomonas vaginalis transcription-mediated amplification-based analyte-specific-reagent testing in a metropolitan setting of high sexually transmitted disease prevalence.

Munson E, Napierala M, Olson R, Endes T, Block T, Hryciuk JE, Schell RF.

J Clin Microbiol. 2008 Oct;46(10):3368-74. doi: 10.1128/JCM.00564-08. Epub 2008 Aug 27.

29.

Interleukin-23 is required for development of arthritis in mice vaccinated and challenged with Borrelia species.

Kotloski NJ, Nardelli DT, Peterson SH, Torrealba JR, Warner TF, Callister SM, Schell RF.

Clin Vaccine Immunol. 2008 Aug;15(8):1199-207. doi: 10.1128/CVI.00129-08. Epub 2008 Jun 25.

30.

Role of IL-17, transforming growth factor-beta, and IL-6 in the development of arthritis and production of anti-outer surface protein A borreliacidal antibodies in Borrelia-vaccinated and -challenged mice.

Nardelli DT, Kevin Luk KH, Kotloski NJ, Warner TF, Torrealba JR, Callister SM, Schell RF.

FEMS Immunol Med Microbiol. 2008 Jul;53(2):265-74. doi: 10.1111/j.1574-695X.2008.00431.x. Epub 2008 Jun 3.

31.

Significantly improved accuracy of diagnosis of early Lyme disease by peptide enzyme-linked immunosorbent assay based on the borreliacidal antibody epitope of Borrelia burgdorferi OspC.

Jobe DA, Lovrich SD, Asp KE, Mathiason MA, Albrecht SE, Schell RF, Callister SM.

Clin Vaccine Immunol. 2008 Jun;15(6):981-5. doi: 10.1128/CVI.00079-08. Epub 2008 Apr 16.

32.

Lyme arthritis: current concepts and a change in paradigm.

Nardelli DT, Callister SM, Schell RF.

Clin Vaccine Immunol. 2008 Jan;15(1):21-34. Epub 2007 Nov 14. Review. No abstract available.

33.

Mechanisms to assess Gram stain interpretation proficiency of technologists at satellite laboratories.

Munson E, Block T, Basile J, Hryciuk JE, Schell RF.

J Clin Microbiol. 2007 Nov;45(11):3754-8. Epub 2007 Aug 29.

34.

Anti-p19 antibody treatment exacerbates lyme arthritis and enhances borreliacidal activity.

Peterson SH, Nardelli DT, Warner TF, Callister SM, Torrealba JR, Schell RF.

Clin Vaccine Immunol. 2007 May;14(5):510-7. Epub 2007 Mar 14.

35.

Borreliacidal OspC antibody response of canines with Lyme disease differs significantly from that of humans with Lyme disease.

Lovrich SD, La Fleur RL, Jobe DA, Johnson JC, Asp KE, Schell RF, Callister SM.

Clin Vaccine Immunol. 2007 May;14(5):635-7. Epub 2007 Mar 7.

36.
37.

Rapid pyrazinamide susceptibility testing of Mycobacterium tuberculosis by flow cytometry.

Fredricks BA, DeCoster DJ, Kim Y, Sparks N, Callister SM, Schell RF.

J Microbiol Methods. 2006 Nov;67(2):266-72. Epub 2006 May 15.

PMID:
16704883
38.

Anti-interleukin-15 prevents arthritis in Borrelia-vaccinated and -infected mice.

Amlong CA, Nardelli DT, Peterson SH, Warner TF, Callister SM, Schell RF.

Clin Vaccine Immunol. 2006 Feb;13(2):289-96.

39.

Interleukin-6 promotes anti-OspA borreliacidal antibody production in vitro.

Munson EL, Nardelli DT, Luk KH, Remington MC, Callister SM, Schell RF.

Clin Vaccine Immunol. 2006 Jan;13(1):19-25.

40.

CD4(+) CD25(+) T cells prevent arthritis associated with Borrelia vaccination and infection.

Nardelli DT, Cloute JP, Luk KH, Torrealba J, Warner TF, Callister SM, Schell RF.

Clin Diagn Lab Immunol. 2005 Jun;12(6):786-92.

41.

Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters.

Lovrich SD, Jobe DA, Schell RF, Callister SM.

Clin Diagn Lab Immunol. 2005 Jun;12(6):746-51. Erratum in: Clin Diagn Lab Immunol. 2005 Sep;12(9):1139.

42.
43.
44.

Neutralization of gamma interferon augments borreliacidal antibody production and severe destructive Lyme arthritis in C3H/HeJ mice.

Munson EL, DeCoster DJ, Nardelli DT, England DM, Callister SM, Schell RF.

Clin Diagn Lab Immunol. 2004 Jan;11(1):35-41.

46.

C-terminal region of outer surface protein C binds borreliacidal antibodies in sera from patients with Lyme disease.

Jobe DA, Lovrich SD, Schell RF, Callister SM.

Clin Diagn Lab Immunol. 2003 Jul;10(4):573-8.

47.

Inhibition of interleukin-17 prevents the development of arthritis in vaccinated mice challenged with Borrelia burgdorferi.

Burchill MA, Nardelli DT, England DM, DeCoster DJ, Christopherson JA, Callister SM, Schell RF.

Infect Immun. 2003 Jun;71(6):3437-42.

48.

Destructive arthritis in vaccinated interferon gamma-deficient mice challenged with Borrelia burgdorferi: modulation by tumor necrosis factor alpha.

Christopherson JA, Munson EL, England DM, Croke CL, Remington MC, Molitor ML, DeCoster DJ, Callister SM, Schell RF.

Clin Diagn Lab Immunol. 2003 Jan;10(1):44-52.

49.

Gamma interferon inhibits production of Anti-OspA borreliacidal antibody in vitro.

Munson EL, Du Chateau BK, Jensen JR, Callister SM, DeCoster DJ, Schell RF.

Clin Diagn Lab Immunol. 2002 Sep;9(5):1095-101.

50.

Ability of the borreliacidal antibody test to confirm lyme disease in clinical practice.

Callister SM, Jobe DA, Agger WA, Schell RF, Kowalski TJ, Lovrich SD, Marks JA.

Clin Diagn Lab Immunol. 2002 Jul;9(4):908-12.

Supplemental Content

Loading ...
Support Center